Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.57 |
| ▸ | ANPEP | P15144 | 4/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15083833 | 1.00 | MMP2 (0.57) | MMP2ANPEPBRD4CYP1A2HIF1A | |
| SCHEMBL8401945 | 0.86 | MMP2 (0.57) | MMP2ANPEPBRD4CYP1A2HIF1A | |
| SCHEMBL8404078 | 0.86 | MMP2 (0.57) | MMP2ANPEPBRD4ALDH1A1CYP19A1 | |
| SCHEMBL8404107 | 0.86 | MMP2 (0.57) | MMP2ANPEPBRD4ALDH1A1CYP19A1 | |
| SCHEMBL3973783 | 0.86 | MMP2 (0.57) | MMP2ANPEPBRD4CYP1A2HIF1A | |
| SCHEMBL8404080 | 0.86 | MMP2 (0.57) | MMP2ANPEPBRD4ALDH1A1CYP19A1 | |
| SCHEMBL8404149 | 0.86 | MMP2 (0.57) | MMP2ANPEPBRD4CYP1A2HIF1A | |
| SCHEMBL4418517 | 0.83 | MMP2 (0.46) | MMP2ANPEPBRD4CYP1A2HIF1A | |
| SCHEMBL19900653 | 0.83 | MMP2 (0.43) | MMP2ANPEPBRD4CYP1A2HIF1A | |
| SCHEMBL22648657 | 0.81 | MMP2 (0.41) | MMP2ANPEPBRD4CYP19A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3331528-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20180099949-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-12 | — | — | US | disclosed |
| EP-2365980-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010077783-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| EP-2086995-A1 | HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2086980-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1963262-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008064066-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064061-A1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007069020-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | MMP2 4628/4885ANPEP 3429/4885BRD4 1410/4885 |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | MMP2 3134/4885ANPEP 2088/4885BRD4 1764/4885 |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | MMP2 4628/4885ANPEP 3429/4885BRD4 1410/4885 |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | MMP2 4628/4885ANPEP 3429/4885BRD4 1410/4885 |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | MMP2 4628/4885ANPEP 3429/4885BRD4 1410/4885 |
| US-20180099949-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | MMP2 4628/4885ANPEP 3429/4885BRD4 1410/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | MMP2 3149/4885ANPEP 411/4885BRD4 1594/4885 |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | MMP2 1855/4885ANPEP 418/4885BRD4 3752/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MMP2 3149/4885ANPEP 411/4885BRD4 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.